

2002 Current Fiscal Year Report: Cancer Advisory Panel for Complementary and Alternative Medicine

Report Run Date: 03/28/2024 11:28:29 PM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2002

3. Committee or Subcommittee

Cancer Advisory Panel for Complementary and Alternative Medicine

3b. GSA

Committee

No.

5269

4. Is this New During Fiscal Year?

No

5. Current Charter

02/26/2001

6. Expected Renewal Date

7. Expected Term Date

08/30/2002

8a. Was Terminated During Fiscal Year?

Yes

8b. Specific Termination Authority

DEPARTMENT DETERMINATION

8c. Actual Term Date

08/30/2002

9. Agency Recommendation for Next Fiscal Year

Terminate

10a. Legislation Req to Terminate?

No

10b. Legislation Pending?

11. Establishment Authority

Authorized by Law

12. Specific Establishment Authority

42 USC 282 (b) (6)

13. Effective Date

11/04/1988

14. Committee Type

Continuing

14c. Presidential?

No

15. Description of Committee

Scientific Technical Program Advisory Board

16a. Total Number of Reports

1

16b. Report Date

09/30/2002

Annual Report to the Secretary

Number of Committee Reports Listed:

1

17a.

Open

1 17b. Closed0 17c. Partially Closed0 Other Activities0 17d. Total 1

Meetings and Dates

Purpose

Start

End

Number of Committee Meetings Listed: 1

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$1,200.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$1,165.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$33,631.00	\$0.00
18a(4). Personnel Pmts to Non-Member Consultants	\$741.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$2,110.00	\$0.00
18b(2). Travel and Per Diem to Federal Members	\$1,322.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$1,845.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$5,310.00	\$0.00
18d. Total	\$47,324.00	\$0.00
19. Federal Staff Support Years (FTE)	0.40	0.00

**20a. How does the Committee accomplish its
purpose?**

The Cancer Advisory Panel for Complementary and Alternative Medicine (CAPCAM) assessed complementary and alternative medicine interventions for cancer, determined potential research opportunities, and recommended mechanisms for further research of promising approaches. This Panel of experts represented a vital step toward rigorously evaluating the efficacy and safety of various complementary and alternative medicine cancer therapies that

demonstrate the potential for helping to reduce the burden of this disease. CAPCAM has reviewed one best case series in FY2002, as well as provided comments on PDQ summary sheets. The National Advisory Council for Complimentary and Alternative Medicine will review and provide advice on these areas in the future.

20b. How does the Committee balance its membership?

The CAPCAM consisted of 15 appointed members. Eleven members were nonfederal and 4 were Federal members. Nonfederal members were selected based on knowledge in the fields of complementary and alternative therapeutic cancer treatments or experience in clinical trials, biostatistics, oncology, mediation, pathology, radiology, and/or bioethics.

20c. How frequent and relevant are the Committee Meetings?

The CAPCAM met one time during FY 02. CAPCAM provided advice regarding the review and assessment of summaries of evidence for complementary and alternative medicine cancer intervention clinical trials submitted by practitioners, evaluation on whether and how these interventions should be followed up and identified future alternative and complementary cancer clinical trials initiatives.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

The CAPCAM was terminated on August 30, 2002. Staff at the National Institutes of Health and the Department of Health and Human Services have determined that the functions of this committee can be assumed by the National Advisory Council for Complimentary and

Alternative Medicine.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Designated Federal Officer

RICHARD NAHIN DIRECTOR, EXTRAMURAL
RESEARCH, TRAINING, AND REVIEW

Committee Members	Start	End	Occupation	Member Designation
CARBONE, PAUL	07/17/2000	04/26/2002	PROFESSOR EMERITUS	Special Government Employee (SGE) Member
CHOYKE, PETER	06/07/1999	08/30/2002	CHIEF, MRI	Special Government Employee (SGE) Member
HAWKINS, MICHAEL	04/01/2002	08/30/2002	ASSOCIATE DIRECTOR	Special Government Employee (SGE) Member
HUFFORD, DAVID	06/28/1999	08/30/2002	PROFESSOR	Special Government Employee (SGE) Member
JONES, LOVELL	08/14/2000	08/30/2002	BIOCHEMIST AND PROFESSOR OF GYNECOLOGIC ONCOLOGY	Special Government Employee (SGE) Member
MOSS, RALPH	04/01/2002	08/30/2002	DIRECTOR	Special Government Employee (SGE) Member
QUELLA, SUSAN	04/01/2002	08/30/2002	NURSE COORDINATOR	Special Government Employee (SGE) Member

SPIEGEL, DAVID	07/12/2000	08/30/2002	PROFESSOR	Special Government Employee (SGE) Member
TRIPATHY, DEBASISH	01/08/2001	08/30/2002	ASSOCIATE CLINICAL PROFESSOR OF MEDICINE	Special Government Employee (SGE) Member
WEED, DOUGLAS	07/12/1999	08/30/2002	CHIEF	Special Government Employee (SGE) Member
WEINSTEIN, SHARON	04/01/2002	08/30/2002	ASSOCIATE PROFESSOR OF ANESTHESIOLOGY, NEUROLOGY AND ONCOLOGY	Special Government Employee (SGE) Member
WHITE, JEFFREY	05/01/1999	08/30/2002	DIRECTOR	Special Government Employee (SGE) Member
WOOD, LAUREN	06/28/1999	08/30/2002	SENIOR CLINICAL INVESTIGATOR	Special Government Employee (SGE) Member

Number of Committee Members Listed: 13

Narrative Description

What are the most significant program outcomes associated with this committee?

Checked if
Applies

- | | |
|----------------------------------|--------------------------|
| Improvements to health or safety | <input type="checkbox"/> |
| Trust in government | <input type="checkbox"/> |
| Major policy changes | <input type="checkbox"/> |
| Advance in scientific research | <input type="checkbox"/> |
| Effective grant making | <input type="checkbox"/> |
| Improved service delivery | <input type="checkbox"/> |
| Increased customer satisfaction | <input type="checkbox"/> |

Implementation of laws or regulatory requirements

☐

Other

☐

Outcome Comments

What are the cost savings associated with this committee?

Checked if Applies

None

☒

Unable to Determine

☐

Under \$100,000

☐

\$100,000 - \$500,000

☐

\$500,001 - \$1,000,000

☐

\$1,000,001 - \$5,000,000

☐

\$5,000,001 - \$10,000,000

☐

Over \$10,000,000

☐

Cost Savings Other

☐

Cost Savings Comments

What is the approximate Number of recommendations produced by this committee for the life of the committee?

0

Number of Recommendations Comments

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

%

% of Recommendations Fully Implemented Comments

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

%

% of Recommendations Partially Implemented Comments

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes ☐ No ☐ Not Applicable ☒

Agency Feedback Comments

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

How is access provided to the information for the Committee's documentation?

Checked if Applies

Contact DFO	<input type="checkbox"/>
Online Agency Web Site	<input type="checkbox"/>
Online Committee Web Site	<input type="checkbox"/>
Online GSA FACA Web Site	<input type="checkbox"/>
Publications	<input type="checkbox"/>

Other



Access Comments